Global

SHERIDAN, WYOMING - December 15, 2025 - ARIDGE has introduced new details on its next-generation A868 flying car concept and confirmed fresh progress at its flying car manufacturing plant, as the company positions two flight systems to serve different segments of China's emerging low-altitude mobility market.

Two flight systems target distinct low-altitude travel needs
ARIDGE framed the low-altitude economy as the next major growth frontier following new energy vehicles, and outlined a dual-product strategy built around different operating missions. The company is developing:

SHERIDAN, WYOMING - December 11, 2025 - A new convergence of obesity dealmaking, regulatory uncertainty at the U.S. Food and Drug Administration (FDA) and fresh neurology data out of the Clinical Trials on Alzheimer's Disease (CTAD) conference is forcing biopharma executives to recalibrate their 2026 playbooks across R&D, partnering and risk management.

Obesity Dealflow Enters a More Competitive, High-Stakes Phase

Pfizer continues to double down on cardiometabolic disease, following its $10 billion acquisition of obesity startup Metsera with an exclusive collaboration to license YaoPharma's oral GLP-1 receptor agonist YP05002. Together with other emerging oral and peptide GLP-1s, this next wave of assets is pushing obesity beyond a single-product, single-modality market and into a diversified, highly competitive landscape.

SHERIDAN, WYOMING - December 11, 2025 - Saol Therapeutics is turning an FDA rejection into a potential regulatory test case, as the biotech prepares to argue that its pyruvate dehydrogenase complex deficiency (PDCD) drug SL1009 is the ideal "poster child" for the agency's new Rare Disease Evidence Principles (RDEP) framework at a Type A meeting on December 18.

Saol Recasts a Complete Response Letter as a Strategic Opening

On September 8, Saol disclosed that the FDA had issued a complete response letter (CRL) for SL1009, an oral formulation of sodium dichloroacetate for children with PDCD, a genetic disorder affecting fewer than 1,000 people in the U.S. The CRL, according to CEO Dave Penake, "suggested that we would need to do an additional adequate and well controlled clinical trial," and that "and that's not feasible to be done by our company and in this patient population."

SHERIDAN, WYOMING - December 11, 2025 - Terns Pharmaceuticals is rapidly emerging as a serious contender in chronic myeloid leukemia (CML), after early clinical data for its allosteric BCR/ABL1 inhibitor TERN-701 more than doubled response rates seen with Novartis' approved STAMP inhibitor Scemblix in comparable settings and sent the biotech's share price sharply higher.

Best-in-Disease Early Efficacy Raises the Bar in CML

At the American Society of Hematology (ASH) annual meeting, Terns reported Phase I data from the CARDINAL trial in previously treated CML patients, with 38 participants evaluable for efficacy. TERN-701 achieved a major molecular response (MMR) rate of 75% at week 24, with 64% of patients reaching MMR overall in the dataset presented. The investigational agent also supported simple once-daily dosing without a food effect, improving convenience relative to many existing tyrosine kinase inhibitor (TKI) regimens.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is expanding its cardiometabolic ambitions through an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to develop, manufacture and commercialize YP05002, an oral GLP-1 receptor agonist currently in Phase 1 for chronic weight management. The deal strengthens Pfizer's position in the fast-moving obesity field and adds a differentiated small-molecule asset to its portfolio of metabolic disease candidates.

Strategic Bet on Small-Molecule GLP-1 in Obesity

Under the agreement, China-based YaoPharma will complete an ongoing Phase 1 study of YP05002 before transferring global development and commercialization rights to Pfizer. For Pfizer, the asset fits neatly into a strategy that aims to pair novel mechanisms with scalable, oral delivery formats for obesity and adjacent cardiometabolic conditions.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is setting the stage for its next financial chapter with an analyst conference call and webcast on December 16, 2025, where the U.S.-based biopharmaceutical leader will present full-year 2026 financial guidance to investors and the broader market. The event underscores how large pharma companies use structured guidance cycles to frame expectations around revenue, R&D investment, pipeline execution and capital allocation.

Anchoring Investor Expectations with 2026 Guidance

Pfizer will host the live call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025, with a simultaneous webcast for global stakeholders. The primary objective is to provide formal full-year 2026 financial guidance, giving clarity on topline trends, margin expectations, R&D spending and the company's capital deployment priorities.

SHERIDAN, WYOMING - December 10, 2025 - Husqvarna Group is sharpening its long-term strategy to deliver profitable growth, unveiling new 2030 financial and sustainability targets and a transformational cost-out program as it positions its global outdoor equipment and robotics portfolio for higher margins and capital efficiency.

New 2030 Strategy Anchored in Portfolio Focus and Operational Excellence

At its Capital Markets Day in Stockholm, Husqvarna Group's leadership team briefed institutional investors, analysts and financial media on the next strategy period to 2030. The company will focus on strategic portfolio management, operational excellence and full leverage of its aftermarket offering across its core manufacturing and industry segments.

SHERIDAN, WYOMING - December 10, 2025 - VisIC Technologies has raised $26 million in a Round B financing that positions its Gallium Nitride (GaN) power devices at the center of the next wave of electric vehicle (EV) drivetrain innovation for global automotive and mobility markets. Led by a global semiconductor leader with Hyundai Motor Company and Kia (HKMC) joining as strategic investor, the funding will help VisIC industrialize its D³GaN™ platform for high-volume traction inverters and adjacent high-voltage applications.

GaN Steps Forward as EV OEMs Push Beyond Silicon and SiC

SHERIDAN, WYOMING - December 10, 2025 - Fresco is stepping up its ambition to become the default operating system for the smart kitchen, closing a €15 million Series C round to accelerate its AI-driven cooking platform for appliance manufacturers and their global consumer base. The Dublin-based company is positioning its KitchenOS and AI Cooking Companion as core infrastructure for appliance OEMs that want to deliver personalized, connected cooking experiences at scale.

From Smart Appliances to an AI-Driven Connected Kitchen Ecosystem

The latest funding round brings together mission-aligned investors focused on the future of food and connected living. New backers include Samuel Dennigan of Strong Roots, Barry Napier of Cubic3 and Tyler Hu of Arda, with continued support from existing investors such as Middleby, ACT Venture Capital, AE Ventures, Morpheus Ventures and Alsop Louie Partners.

SHERIDAN, WYOMING - December 10, 2025 - From its position as a fast-rising global capital hub, Abu Dhabi is using Abu Dhabi Finance Week's Asset Abu Dhabi forum to redefine how institutional investors think about asset allocation, risk and long-term value creation in a volatile macro environment. Hosted by Abu Dhabi Global Market (ADGM), the event's second day brought together leading capital allocators, hedge fund managers, family office leaders and policymakers to assess emerging opportunities and the next frontier of asset management.

Abu Dhabi's regulatory platform moves into the global first rank